REGENXBIO Inc. (RGNX) Spending and interest coverage
- R&D / revenue · 12 months: Value 131.32%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 20.08%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 131.32% | Research and development expense / revenue. Period ending 2026-06-30. $229.14M ÷ $174.48M × 100 ≈ 131.32% |
| Stock-based compensation / revenue · 12 months | 20.08% | Share-based compensation / revenue. Period ending 2026-06-30. $35.04M ÷ $174.48M × 100 ≈ 20.08% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 229.14M USD | Research and Development Expense |
| Revenue | 174.48M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 35.04M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -164.15M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $229.14M | $174.48M | $35.04M | $-164.15M | (m) | 131.32% | 20.08% | (m) | (m) |
| 2026-03-31 | $232.55M | $87.82M | $34.64M | $-256.69M | (m) | 264.80% | 39.45% | (m) | (m) |
| 2025-12-31 | $228.30M | $170.44M | $34.56M | $-161.20M | (m) | 133.95% | 20.28% | (m) | (m) |
| 2025-09-30 | $219.07M | $161.32M | $35.73M | $-154.93M | (m) | 135.80% | 22.15% | (m) | (m) |
| 2025-06-30 | $217.40M | $155.78M | $36.62M | $-164.60M | (m) | 139.55% | 23.50% | (m) | (m) |
| 2025-03-31 | $206.76M | $156.72M | $37.40M | $-157.36M | (m) | 131.93% | 23.86% | (m) | (m) |
| 2024-12-31 | $208.52M | $83.33M | $38.46M | $-233.35M | (m) | 250.24% | 46.16% | (m) | (m) |
| 2024-09-30 | $213.82M | $84.33M | $37.26M | $-245.88M | (m) | 253.56% | 44.18% | (m) | (m) |
| 2024-06-30 | $217.58M | $89.04M | $37.59M | $-248.76M | $5.41M | 244.35% | 42.22% | -45.99× | Reported |
| 2024-03-31 | $228.59M | $86.73M | $38.66M | $-265.83M | $6.08M | 263.58% | 44.58% | -43.72× | Reported |
| 2023-12-31 | $232.27M | $90.24M | $40.27M | $-268.13M | $6.86M | 257.38% | 44.62% | -39.07× | Reported |
| 2023-09-30 | $239.09M | $99.37M | $41.34M | $-262.00M | $9.81M | 240.60% | 41.60% | -26.71× | Reported |
| 2023-06-30 | $244.22M | $96.97M | $41.36M | $-268.08M | $14.14M | 251.85% | 42.65% | -18.96× | Reported |
| 2023-03-31 | $245.34M | $109.64M | $41.19M | $-257.51M | $19.88M | 223.76% | 37.57% | -12.95× | Reported |
| 2022-12-31 | $242.45M | $112.72M | $40.79M | $-262.88M | $23.25M | 215.09% | 36.18% | -11.30× | Reported |
| 2022-09-30 | $227.93M | $480.03M | $40.54M | $108.49M | $25.44M | 47.48% | 8.45% | 4.26× | Reported |
| 2022-06-30 | $212.47M | $484.30M | $40.03M | $122.19M | $26.20M | 43.87% | 8.27% | 4.66× | Reported |
| 2022-03-31 | $197.34M | $473.68M | $39.69M | $132.50M | $25.70M | 41.66% | 8.38% | 5.15× | Reported |
| 2021-12-31 | $181.44M | $470.35M | $38.81M | $159.98M | $26.28M | 38.58% | 8.25% | 6.09× | Reported |
| 2021-09-30 | $180.64M | $93.14M | $37.23M | $-207.27M | (m) | 193.95% | 39.97% | (m) | (m) |
| 2021-06-30 | $176.75M | $161.28M | $35.53M | $-135.97M | (m) | 109.60% | 22.03% | (m) | (m) |
| 2021-03-31 | $168.98M | $155.81M | $33.85M | $-125.58M | (m) | 108.46% | 21.73% | (m) | (m) |
| 2020-12-31 | $166.29M | $154.57M | $31.95M | $-119.23M | $771.00K | 107.59% | 20.67% | -154.65× | Reported |
| 2020-09-30 | $152.92M | $144.89M | $31.24M | $-105.91M | (m) | 105.54% | 21.56% | (m) | (m) |
| 2020-06-30 | $144.65M | $60.68M | $30.37M | $-155.75M | (m) | 238.38% | 50.05% | (m) | (m) |
| 2020-03-31 | $136.02M | $51.99M | $29.15M | $-150.79M | (m) | 261.61% | 56.07% | (m) | (m) |
| 2019-12-31 | $124.19M | $35.23M | $26.85M | $-149.00M | (m) | 352.47% | 76.22% | (m) | (m) |
| 2019-09-30 | $114.71M | $64.24M | $24.86M | $-106.22M | (m) | 178.55% | 38.71% | (m) | (m) |
| 2019-06-30 | $97.52M | $54.85M | $22.19M | $-93.05M | (m) | 177.81% | 40.45% | (m) | (m) |
| 2019-03-31 | $89.53M | $87.00M | $19.07M | $-49.83M | (m) | 102.91% | 21.92% | (m) | (m) |
| 2018-12-31 | $83.87M | $218.50M | $16.64M | $88.10M | (m) | 38.38% | 7.62% | (m) | (m) |
| 2018-09-30 | $73.71M | $179.77M | $14.55M | $69.05M | (m) | 41.01% | 8.09% | (m) | (m) |
| 2018-06-30 | $67.72M | $175.80M | $12.80M | $70.47M | (m) | 38.52% | 7.28% | (m) | (m) |
| 2018-03-31 | $60.16M | $142.33M | $11.30M | $49.06M | (m) | 42.26% | 7.94% | (m) | (m) |
| 2017-12-31 | $57.22M | $10.39M | $10.61M | $-75.89M | (m) | 550.60% | 102.04% | (m) | (m) |
| 2017-09-30 | $59.11M | $10.05M | $9.81M | $-79.76M | (m) | 588.25% | 97.61% | (m) | (m) |
| 2017-06-30 | $59.16M | $8.84M | $8.90M | $-77.11M | (m) | 669.33% | 100.74% | (m) | (m) |
| 2017-03-31 | $55.92M | $4.65M | $8.08M | $-77.01M | (m) | 1202.28% | 173.64% | (m) | (m) |
| 2016-12-31 | $45.48M | $4.59M | $7.03M | $-65.34M | (m) | 991.11% | 153.21% | (m) | (m) |
| 2016-09-30 | $34.23M | $7.34M | $5.89M | $-50.37M | (m) | 466.30% | 80.28% | (m) | (m) |
| 2016-06-30 | $27.34M | $8.35M | $5.41M | $-39.05M | (m) | 327.45% | 64.82% | (m) | (m) |
| 2016-03-31 | $20.67M | $7.34M | $4.39M | $-30.39M | (m) | 281.74% | 59.85% | (m) | (m) |
| 2015-12-31 | $17.28M | $7.59M | $2.92M | $-23.14M | $20.00K | 227.71% | 38.49% | -1156.85× | Reported |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $3.64M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $3.83M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $4.96M | $6.12M | $319.00K | $-3.68M | $321.00K | 81.06% | 5.21% | -11.47× | Reported |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $5.05M | $6.09M | (m) | $-4.78M | $611.00K | 82.98% | (m) | -7.82× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |